Alvotech’s non-license product sales nearly trebled to $65.9m in the first six months of the year, as the firm outlined expectations for its product revenues to overtake lower milestone revenues towards the end of 2024, amid solid gains for the Icelandic firm’s interchangeable high-concentration 100mg/ml Simlandi (adalimumab-ryvk) in the US.
Alvotech Beginning To Take Flight As Product Sales Treble In H1
Three Filings In Major Markets Slated For This Year, Including Golimumab
Driven by increased orders, Alvotech is bullish on its US adalimumab biosimilar moving into 2025, as it also look forward to the US launch for its Stelara biosimilar early next year.
